Dengue virus (DENV) is a mosquito-borne flavivirus that poses a threat to nearly 50% of the global population. DENV has been endemic in Nepal since 2006; however, little is known about how DENV is evolving or the prevalence of anti-DENV immunity within the Nepalese population. To begin to address these gaps, we performed a serologic and genetic study of 49 patients from across Nepal who presented at central hospitals during the 2017 dengue season with suspected DENV infection. Of the 49 subjects assessed, 21 (43%) were positive for DENV NS1 antigen; of these; 5 were also anti-DENV IgM+ IgG+; 7 were DENV IgM+ IgG-, 2 were IgM- IgG+, and 7 were IgM-IgG- by specific ELISAs. Seven of the 21 NS1 positive sera were RNA positive by RT-PCR (six DENV2, one DENV3), suggesting that DENV2 was the dominant serotype in our cohort. Whole-genome sequencing of two DENV2 isolates showed similarity with strains circulating in Singapore in 2016, and the envelope genes were also similar to strains circulating in India in 2017. DENV-neutralizing antibodies (nAbs) were present in 31 of 47 sera tested (66%); among these, 20, 24, 26, and 12 sera contained nAbs against DENV1, 2, 3, and 4 serotypes, respectively. Additionally, 27 (58%) samples had nAbs against multiple serotypes (2 or more). Serology analysis suggested that 12 (26%) and 19 (40%) of the 47 subjects were experiencing primary and secondary DENV infections, respectively. Collectively, our results provide evidence for current and/or past exposure to multiple DENV serotypes in our cohort. These data suggest that expanded local surveillance of circulating DENV genotypes and population immunity will be important to effectively manage and mitigate future dengue outbreaks in Nepal.

Reference:
Prajapati, S., Elong Ngono, A., Mc Cauley, M., Timis, J., Shrestha, S., Bastola, A., Mandal, S. K., Ray Yadav, S., Napit, R., Moi, M. L., Yamabhai, M., M Sessions, O., Shresta, S., & Manandhar, K. D. (2024). Genomic sequencing and neutralizing serological profiles during acute dengue infection: A 2017 cohort study in Nepal. PLOS global public health, 4(11), e0002966. https://doi.org/10.1371/journal.pgph.0002966
Access Research Paper here

Study Collaborators:
・Infectious and Viral Disease Research Laboratory, Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal
・Sukraraj Tropical and Infectious Disease Hospital, Teku, Kathmandu, Nepal
・Department of Haematology and Biochemistry, Chitwan Medical College and Teaching Hospital, Chitwan, Nepal
・Infectious and Viral Disease Research Laboratory, Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal
・Molecular Biotechnology Laboratory, School of Biotechnology, Institute of Agricultural Technology, Suranaree University of Technology, Nakhon Ratchasima, Thailand
・Saw Swee Hock School of Public Health, National University of Singapore, Singapore
・Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA